13F Holdings
中文EN

BTCY BIOTRICITY INC.

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1630113 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY11.7%
TTM net income YoY38.0%
TTM EPS YoY-4.9%
Revenue 3-yr CAGR14.9%
Net income 3-yr CAGR—

Margins

Gross margin81.8%
Operating margin9.7%
Net margin-16.7%
FCF margin—
EBITDA margin9.7%

Returns

ROE—
ROA-45.2%
ROIC (approx.)—
Asset turnover2.71x

Leverage & solvency

Liabilities / assets662.7%
Debt / equity—
Current ratio0.15x
Interest coverage0.49x

Cash quality & payout

Operating cash flow / net income0.09x
Accruals ratio-41.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-03-31FY20252025-03-31FY20242024-03-31FY20232023-03-31FY20222022-03-31
Income statement
Revenue$16.00M$13.79M$12.06M$9.64M$7.65M
Cost of revenue$3.05M$3.23M$3.71M$4.20M$3.08M
Gross profit$12.95M$10.56M$8.36M$5.44M$4.57M
R&D expense$2.76M$2.16M$2.57M$3.23M$2.74M
SG&A expense$8.49M$10.86M$14.61M$17.62M$18.56M
Operating income$1.69M-$2.45M-$8.83M-$15.41M-$16.74M
Interest expense$3.36M$3.26M$3.02M$1.84M$1.28M
Pretax income-$2.40M-$8.42M-$14.09M-$18.66M-$29.13M
Net income-$2.40M-$8.42M-$14.09M-$18.66M-$29.13M
EBITDA$1.70M-$2.44M-$8.82M-$15.40M-$16.73M
EPS (basic)-0.12-0.56-1.66-2.26-0.67
EPS (diluted)-0.12-0.56-1.66-2.26—
Weighted avg. shares (diluted)27.30M21.52M8.99M8.66M—
Balance sheet
Cash & equivalents$149,789$365,145$786,060$570,460$12.07M
Receivables$2.93M$1.66M$1.47M$1.22M$2.01M
Inventory$1.34M$1.56M$1.88M$2.34M$842,924
Current assets$5.86M$4.64M$4.47M$4.72M$15.32M
PP&E, net$3,646$9,599$15,552$21,506$21,506
Total assets$6.45M$5.64M$5.94M$6.51M$16.68M
Current liabilities$37.14M$20.64M$22.70M$11.16M$4.87M
Total liabilities$39.41M$35.66M$35.92M$26.36M$18.82M
Shareholders' equity-$34.68M-$32.01M-$31.47M-$19.85M-$2.14M
Shares outstanding28.60M26.08M9.35M8.51M49.81M
Cash flow statement
Operating cash flow-$718,955-$2.38M-$6.69M-$13.55M-$15.16M
Capital expenditure————$29,767
Free cash flow————-$15.19M
Investing cash flow————-$29,767
Financing cash flow$557,736$1.93M$6.74M$2.00M$25.17M
Depreciation & amortization$5,953$5,953$5,953$5,953$2,308
Stock-based compensation$25,632$1.46M$1.03M$647,631$913,613

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.